Instil Bio

TIL · NASDAQ

$5.94+$0.15 (+2.59%)TodayMarket closed · Oct 20, 5:35 PM ET

Prev close $5.79

TIL analyst rating

HoldConsensus of 1 analyst over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold1
Underperform0
Sell0

12-month price target · 2 analysts

Average $7.14 (+20.2% upside)

Low: $7.07
Now: $5.94
High: $7.35

Upgrades and downgrades

The latest rating actions, newest first

TIL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Hit rate
HC Wainwright & Co.	Jan 7, 2026	Downgrade	Buy → Neutral	32%

The case for and against

Updated Feb 9, 2026

Bull case

Instil Bio Inc's focus on developing a unique pipeline of autologous tumor infiltrating lymphocyte therapies, including the CoStAR platform, positions it well within the evolving oncology landscape. The potential of its ITIL-306 therapy, which targets a tumor-associated antigen prevalent in various solid tumors, underscores the company's innovative approach and expands its therapeutic reach. Furthermore, the anticipated positive updates from related therapeutic classes may enhance investor sentiment, creating a favorable environment for Instil Bio's continued growth and valuation upside.

Bear case

Instil Bio Inc's stock outlook has been negatively impacted by the discontinuation of AXN-2510, which was a core value driver, necessitating a comprehensive reassessment of the company's financial thesis. There are significant risks associated with potential delays in advancing clinical candidates, the failure to produce positive clinical data, and concerns over medium- to long-term dilution, all contributing to investor uncertainty. The absence of strategic clarity has positioned the stock as lacking momentum in the short term, with its enterprise value trading slightly below cash levels, highlighting the challenging financial circumstances the company faces.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.